The diabetes drug, sold by Eli Lilly and Company under the brand names Zepbound and Mounjaro, was associated with better outcomes, improved symptoms and more significant weight loss than a placebo.

Reviewing a patient's medical history can help care teams select the optimal post-TAVR oral anticoagulation strategy.

The new PREVENT CVD risk calculator could result in more than 16 million heart patients who are no longer eligible for preventive therapy. These significant changes “carry the potential for both benefit and harm," researchers wrote in JAMA.

Compounded semaglutide injectable products are at the heart of these concerns. While the FDA says compounded drugs “can serve an important medical need for patients,” the agency does not approve these new formulations, increasing the risk of complications. 

Businesses in the cardiovascular health space have been busy in recent weeks, announcing one big financing round after another. 

Researchers described pharmacies as an “attractive setting for community-based AFib screening."

The American Medical Association has a collection of artifacts on health fraud quackery at its Chicago headquarters office.

Both tirzepatide (Mounjaro) and semaglutide (Ozempic) have made headlines in recent months for their benefits in broad patient populations. This new analysis compared the two medications in obese/overweight adults with and without type 2 diabetes.